Drug intelligence / Profile preview

SHS

Development stage: Preclinical
Lead developer: Affiliated Hospital of Southwest Medical University
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Transdermal

Overview

SHS is a spreadable, high-efficiency transdermal delivery system, likely a gel formulation, designed to enhance the delivery of 5-fluorouracil for the treatment of hypertrophic scars. It is being investigated in a prospective, randomized controlled clinical trial as part of a combination therapy that includes 5-fluorouracil and MUCA, potentially utilizing microneedle technology for improved efficacy.

Beyond the preview

Go deeper on SHS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHS.

Explore the full profile